Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03210961 · ClinicalTrials.gov registry record · Phase 1
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 109
- Enrollment target
NCT03210961 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 109 participants.
The verdict
NCT03210961, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 109 participants
- Enrollment target
Study Summary
This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.
Interventions
- OTHER Placebo tablet
- DRUG PF-06826647 tablet
- DRUG PF-06826647 oral suspension
- OTHER Placebo oral solution/suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2017-07-14 |
| Est. Completion | 2019-01-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03210961
The ClinicalTrials.gov registry entry for NCT03210961 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo tablet is the first listed.
NCT03210961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03210961 about?
NCT03210961 is a clinical study titled "A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis". This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.
What is the current status of trial NCT03210961?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 109 participants. The study started on 2017-07-14. Estimated completion is 2019-01-25.
What interventions are being tested in trial NCT03210961?
The interventions under investigation include: Placebo tablet (OTHER), PF-06826647 tablet (DRUG), PF-06826647 oral suspension (DRUG), Placebo oral solution/suspension (OTHER).
Who is sponsoring clinical trial NCT03210961?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.